	Application No.	Applicant(s)
Notice of Allowability	09/306,006 Examiner	SUPERSAXO ET AL. Art Unit
	Shahnam Sharareh	1617
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGOT (The Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication GHTS. This application is subject to	plication. If not included not will be mailed in due course. THIS
1. This communication is responsive to <u>10/24/2005</u> .		
2. The allowed claim(s) is/are <u>2,6,16,17,19-21,28 and 30</u> .		
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) All b) Some* c) None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which gives	tted. Note the attached EXAMINER s reason(s) why the oath or declara	'S AMENDMENT or NOTICE OF ation is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.8 each sheet. Replacement sheet(s) should be labeled as such in the	B4(c)) should be written on the drawir he header according to 37 CFR 1.121(ngs in the front (not the back) of d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	- Floring (1.6)	
1. Notice of References Cited (PTO-892)	_	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary Paper No./Mail Dat 	(PTO-413), e .
 Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 	B), 7. ⊠ Examiner's Amendr	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material Output Description:	8. Examiner's Stateme	ent of Reasons for Allowance
of biological Material	9.	
		i

Art Unit: 1617

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Tyler Stevenson on March 2, 2006.

The application has been amended as follows:

Amend Claim 6 to read: A method according to claim 28 wherein the nanodispersion comprises as component (a) a compound selected from the group consisting of a phospholipids, a hydrated or partially hydrated phospholipids, a lysophospholipid, and mixtures thereof.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance: the prior art does not teach methods of preparing an aqueous monodispersion nanodispersion wherein the average sizes of particle diameter is <50nm and wherein the dispersion is prepared by mixing the recited polyoxyethylene coemulsifiers with the phospholipids, lipidic component and ethanol in the claimed amounts and then adding to the mixture a water phase in the absence of high shear or cavitation forces. Further, the prior art does not suggest the unexpected improvement in clarity and stability of the prepared product when the phospholipids component and the polyoxyethylene coemulsifiers of the instant process are used together.

Application/Control Number: 09/306,006

Art Unit: 1617

Page 3

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shahnam Sharareh whose telephone number is 571-272-0630. The examiner can normally be reached on 8:30 am - 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, PhD can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SS